The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis
Injectable GLP-1 drugs reduce deaths and heart attacks in diabetes, with specific agents showing the strongest heart protection in head-to-head comparisons.
This network meta-analysis of 15 RCTs (n=97,173) provides updated agent-level comparative estimates for GLP-1-based therapies in T2DM cardiovascular outcomes, confirming a class-level reduction in all-cause mortality, CV death, and MACE vs placebo. Injectable semaglutide, efpeglenatide, and albiglutide emerged as having the most favorable MACE profiles in agent-level comparisons, providing actionable prescribing guidance.
What the study was
- Study design
- Systematic review and network meta-analysis of 15 RCTs
- Population
- Adults with type 2 diabetes mellitus from 15 cardiovascular outcome trials; 97,173 participants
- Sample size
- 97173
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Diabetes Obes Metab
Why it surfaced
Largest-to-date NMA (97,173 participants, 15 RCTs) confirming class-level CV mortality benefit and providing agent-level differentiation for GLP-1 therapies in T2DM; directly informs prescribing decisions in a high-prevalence, high-burden condition.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.